Cargando…
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
IMPORTANCE: It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor prognosis. Previous reports of the HER2CLIMB trial have demonstrated that tucatinib in combination with trastuzumab and...
Autores principales: | Lin, Nancy U., Murthy, Rashmi K., Abramson, Vandana, Anders, Carey, Bachelot, Thomas, Bedard, Philippe L., Borges, Virginia, Cameron, David, Carey, Lisa A., Chien, A. Jo, Curigliano, Giuseppe, DiGiovanna, Michael P., Gelmon, Karen, Hortobagyi, Gabriel, Hurvitz, Sara A., Krop, Ian, Loi, Sherene, Loibl, Sibylle, Mueller, Volkmar, Oliveira, Mafalda, Paplomata, Elisavet, Pegram, Mark, Slamon, Dennis, Zelnak, Amelia, Ramos, Jorge, Feng, Wentao, Winer, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716438/ https://www.ncbi.nlm.nih.gov/pubmed/36454580 http://dx.doi.org/10.1001/jamaoncol.2022.5610 |
Ejemplares similares
-
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020) -
53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020) -
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
por: Sirhan, Zaid, et al.
Publicado: (2022) -
Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023) -
Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
por: Ulrich, Lara, et al.
Publicado: (2021)